Asterias Biotherapeutics Inc. (AST) 4.92 $AST A
Post# of 273322
Posted On: 08/01/2015 2:45:41 AM
Asterias Biotherapeutics Inc. (AST) 4.92 $AST
Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015
PR Newswire - Wed Jul 29, 3:01PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Monday, August 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate developments.
AST: 4.92 (+0.05)
Will Asterias (AST) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:28AM CDT
Will Asterias (AST) Continue to Surge Higher?
AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Looks Good: Stock Up 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 8:25AM CDT
Asterias Biotherapeutics (AST) was a big mover last session, with shares rising over 13% on the day.
AST: 4.92 (+0.05), AMAG: 63.90 (-0.87)
OncoCyte Announces Appointment of Andy Arno to Board of Directors
Business Wire - Wed Jul 15, 7:30AM CDT
-- OncoCyte is Advancing Three Non-invasive Cancer Diagnostics Through Clinical Trials
BTX: 3.16 (-0.07), AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 10, 8:34AM CDT
Asterias Biotherapeutics (AST) Is in Oversold Territory: What's Next?
AST: 4.92 (+0.05)
Chardan Capital Markets Announces Hiring of Andy Arno to The Special Equities Group
PR Newswire - Tue Jul 07, 9:56AM CDT
Chardan Capital Markets, a privately held investment banking firm announced today that Andrew Arno has been appointed as "Vice Chairman of The Special Equities Group".
SMSI: 0.98 (-0.02), AST: 4.92 (+0.05)
Asterias Biotherapeutics, Inc. (AST) in Focus: Stock Surges 24.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 8:21AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares surge over 24% on the day.
CBM: 49.25 (-0.68), AST: 4.92 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 11:47AM CDT
AMRS: 1.63 (-0.06), ADXS: 16.66 (+0.84), GMAN: 5.51 (+0.02), ESI: 3.68 (-0.22), AEHR: 2.24 (+0.03), CLF: 2.52 (-0.13), EPZM: 22.31 (-0.02), FBP: 4.31 (-0.09), PDII: 2.13 (unch), PRSN: 0.56 (+0.01), MHR: 0.96 (-0.05), AOI: 22.60 (+0.80), FENX: 9.14 (+0.14), COOL: 1.49 (-0.02), OFG: 8.06 (-0.15), SKYS: 9.00 (+0.74), AST: 4.92 (+0.05), BBLU: 1.02 (+0.05)
Asterias Bio added to Russell indexes; shares up 39%
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 9:42AM CDT
AST: 4.92 (+0.05)
Asterias Biotherapeutics Added To Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® Indexes
PR Newswire - Tue Jun 30, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® indexes following Russell Investments' ("Russell"
reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. Each June, Russell completely rebalances its indexes, known as a reconstitution, to reflect market changes in the past year.
AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Jumps: Stock Moves Up 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 17, 7:51AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as its shares rose over 5% on the day.
CBM: 49.25 (-0.68), AST: 4.92 (+0.05)
BioTime's Prospectus Setting Up Potential Divestiture Of Asterias Becomes Effective
JMY Investments - at Seeking Alpha - Mon Jun 15, 9:48AM CDT
OCAT: 4.49 (+0.24), BTX: 3.16 (-0.07), AST: 4.92 (+0.05)
Preliminary Reconstitutions of Russell 3000®, Russell Global and Russell Microcap® Indexes Include Asterias Biotherapeutics
PR Newswire - Mon Jun 15, 8:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine is included in the preliminary list of additions to three Russell Investments ("Russell" indexes. According to information published by Russell, Asterias is expected to be added to the Russell 3000®, Russell Global and Russell Microcap® indexes when Russell reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2015.
AST: 4.92 (+0.05)
Asterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
PR Newswire - Mon Jun 08, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the first patient was successfully dosed at the Atlanta-based Shepherd Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). The Phase 1/2a trial is part of the planned registration program for AST-OPC1, with neurologically complete cervical SCI as the first targeted indication.
AST: 4.92 (+0.05)
Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
PR Newswire - Mon Jun 01, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML). AST-VAC1 is the Company's autologous (using cells sourced from the patient) telomerase-based dendritic cell cancer vaccine. AML is the most common form of acute leukemia in adults with 12,000 new cases diagnosed annually, and remains an unmet clinical need, especially in patients over the age of 60 who face poor outcomes and have limited therapies available to them. The long-term follow-up showed that more than 50% of patients who received AST-VAC1 had prolonged relapse-free survival, even patients with high-risk AML including those over 60 years old and patients in second remission.
AST: 4.92 (+0.05)
Asterias Biotherapeutics to Report Second Quarter Results on August 10, 2015
PR Newswire - Wed Jul 29, 3:01PM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a leading biotechnology company in the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 10, 2015 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Monday, August 10, 2015 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the results and corporate developments.
AST: 4.92 (+0.05)
Will Asterias (AST) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 8:28AM CDT
Will Asterias (AST) Continue to Surge Higher?
AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Looks Good: Stock Up 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 17, 8:25AM CDT
Asterias Biotherapeutics (AST) was a big mover last session, with shares rising over 13% on the day.
AST: 4.92 (+0.05), AMAG: 63.90 (-0.87)
OncoCyte Announces Appointment of Andy Arno to Board of Directors
Business Wire - Wed Jul 15, 7:30AM CDT
-- OncoCyte is Advancing Three Non-invasive Cancer Diagnostics Through Clinical Trials
BTX: 3.16 (-0.07), AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 10, 8:34AM CDT
Asterias Biotherapeutics (AST) Is in Oversold Territory: What's Next?
AST: 4.92 (+0.05)
Chardan Capital Markets Announces Hiring of Andy Arno to The Special Equities Group
PR Newswire - Tue Jul 07, 9:56AM CDT
Chardan Capital Markets, a privately held investment banking firm announced today that Andrew Arno has been appointed as "Vice Chairman of The Special Equities Group".
SMSI: 0.98 (-0.02), AST: 4.92 (+0.05)
Asterias Biotherapeutics, Inc. (AST) in Focus: Stock Surges 24.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 01, 8:21AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as the company saw its shares surge over 24% on the day.
CBM: 49.25 (-0.68), AST: 4.92 (+0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 11:47AM CDT
AMRS: 1.63 (-0.06), ADXS: 16.66 (+0.84), GMAN: 5.51 (+0.02), ESI: 3.68 (-0.22), AEHR: 2.24 (+0.03), CLF: 2.52 (-0.13), EPZM: 22.31 (-0.02), FBP: 4.31 (-0.09), PDII: 2.13 (unch), PRSN: 0.56 (+0.01), MHR: 0.96 (-0.05), AOI: 22.60 (+0.80), FENX: 9.14 (+0.14), COOL: 1.49 (-0.02), OFG: 8.06 (-0.15), SKYS: 9.00 (+0.74), AST: 4.92 (+0.05), BBLU: 1.02 (+0.05)
Asterias Bio added to Russell indexes; shares up 39%
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 9:42AM CDT
AST: 4.92 (+0.05)
Asterias Biotherapeutics Added To Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® Indexes
PR Newswire - Tue Jun 30, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000®, Russell 3000®, Russell Global and Russell Microcap® indexes following Russell Investments' ("Russell"
reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. Each June, Russell completely rebalances its indexes, known as a reconstitution, to reflect market changes in the past year. AST: 4.92 (+0.05)
Asterias Biotherapeutics (AST) Jumps: Stock Moves Up 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 17, 7:51AM CDT
Asterias Biotherapeutics, Inc. (AST) was a big mover last session, as its shares rose over 5% on the day.
CBM: 49.25 (-0.68), AST: 4.92 (+0.05)
BioTime's Prospectus Setting Up Potential Divestiture Of Asterias Becomes Effective
JMY Investments - at Seeking Alpha - Mon Jun 15, 9:48AM CDT
OCAT: 4.49 (+0.24), BTX: 3.16 (-0.07), AST: 4.92 (+0.05)
Preliminary Reconstitutions of Russell 3000®, Russell Global and Russell Microcap® Indexes Include Asterias Biotherapeutics
PR Newswire - Mon Jun 15, 8:00AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine is included in the preliminary list of additions to three Russell Investments ("Russell"
indexes. According to information published by Russell, Asterias is expected to be added to the Russell 3000®, Russell Global and Russell Microcap® indexes when Russell reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2015. AST: 4.92 (+0.05)
Asterias Biotherapeutics Announces First Patient Treated in Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
PR Newswire - Mon Jun 08, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that the first patient was successfully dosed at the Atlanta-based Shepherd Center in a Phase 1/2a clinical trial evaluating activity of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI). The Phase 1/2a trial is part of the planned registration program for AST-OPC1, with neurologically complete cervical SCI as the first targeted indication.
AST: 4.92 (+0.05)
Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics' AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
PR Newswire - Mon Jun 01, 5:30AM CDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML). AST-VAC1 is the Company's autologous (using cells sourced from the patient) telomerase-based dendritic cell cancer vaccine. AML is the most common form of acute leukemia in adults with 12,000 new cases diagnosed annually, and remains an unmet clinical need, especially in patients over the age of 60 who face poor outcomes and have limited therapies available to them. The long-term follow-up showed that more than 50% of patients who received AST-VAC1 had prolonged relapse-free survival, even patients with high-risk AML including those over 60 years old and patients in second remission.
AST: 4.92 (+0.05)
(0)
(0)